Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 626-635

  Aliabadi, F Shojaee ^a   Landoni, M F ^b   Lees, P ^c  

^a Food Quality Control Laboratory   (Iran)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DANOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL DISEASE; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BODY FLUID; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MODEL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DESIGN; EXUDATE; INFLAMMATION; MANNHEIMIA HAEMOLYTICA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHEEP; STRAIN IDENTIFICATION;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FLUOROQUINOLONES; HALF-LIFE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MANNHEIMIA HAEMOLYTICA; MICROBIAL SENSITIVITY TESTS; SHEEP; TISSUE DISTRIBUTION;

EID: 0037308569     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.626-635.2003     Document Type: Article

References (33)

1. Appelbaum, P. C., and P. A. Hunter. 2000. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 16:5-15.
2. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
3. Cooper, A. C., J. R. Fuller, M. K. Fuller, P. Whittlestone, and D. R. Wise. 1993. In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance. Res. Vet. Sci. 54:329-334.
4. Czock, D., M., and M. Giehl. 1995. Aminoglycoside pharmacokinetics and dynamics: a nonlinear approach. Int. J. Clin. Pharmacol. Ther. 33:537-539.
5. Dalhoff, A., and U. Ullmann. 1990. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur. J. Clin. Microbiol. Infect. Dis. 9: 479-487.
6. Drusano, G. L., D. E. Johnson, M. Rosen, and H. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37: 483-490.
7. Dudley, M. N. 1991. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am. J. Med. 91(Suppl. 6A): 455-505.
8. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
9. Friis, C. 1993. Penetration of danofloxacin into the respiratory tract tissues and secretion in calves. Am. J. Vet. Res. 54:1122-1127.
10. Giles, C. J. 1991. Danofloxacin. A new antimicrobial for therapy of infectious respiratory diseases in cattle and swine, p. 87-96. In Proceedings of the Royal Veterinary College/Pfizer Symposium on Respiratory Disease in Cattle and Pigs. The Royal Veterinary College, Hatfield, United Kingdom.
11. Giles, C. J., R. A. Magonigle, W. T. R. Grimshaw, et al. 1991. Clinical pharmacokinetics of administered danofloxacin in cattle. J. Vet. Pharmacol. Ther. 14: 400-410.
12. Grimshaw, W. T. R., C. J. Giles, A. C. Cooper, and D. J. Shanks. 1990. The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves. Dtsch. Tierarztl. Wochenschr. 97:529-532.
13. Hannan, P. C. T., P. J. O'Hanlon, and N. M. Rogers. 1989. In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens. Res. Vet. Sci. 46:202-211.
14. Hooper, D. C., and J. S. Wolfson. 1991. Mode of action of the new quinolones: new data. Eur. J. Clin. Microbiol. Infect. Dis. 10:222-231.
15. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetics and pharmacodynamics of ciprofloxacin against similar MIC strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa using kill curve methodology. Antimicrob. Agents Chemother. 38:2730-2737.
16. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome, focus on antibacterial agents. Clin. Pharm. Concepts 28:143-160.
17. Lees, P., and F. Shojaee AliAbadi. 2000. Rationalising dosage regimens of antimicrobial drugs: a pharmacological perspective. J. Med. Microbiol. 49: 943-945.
18. Lees, P., and F. Shojaee AliAbadi, 2002. Rational dosing of antimicrobial drugs: animals versus humans. Int. J. Antimicrob. Agents 19:269-284.
19. Leggett, J. E., R. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J. Infect. Dis. 159:281-290.
20. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose-effect relationships at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74:179-184.
21. McGuirk, P. R., M. R. Jefson, D. D. Mann, N. C. Eliott, P. Chang, E. P. Cisek, C. P. Cornell, T. D. Gootz, S. L. Haskell, M. S. Hindahl, et al. 1992. Synthesis and structure-activity relationship of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J. Med. Chem. 35:611-621.
22. McKellar, Q. A., F. I. Gibson, and Z. R. McCormack. 1998. Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm. Drug Dispos. 19:123-129.
23. McKellar, Q. A., F. I. Gibson, A. Monteiro, and M. Bregante. 1999. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. Antimicrob. Agents Chemother. 43:1988-1992.
24. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
25. Neu, H.C. 1991. Synergy and antagonism of combinations with quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 10:255-261.
26. Nicolau, D. P., R. Quintiliani, and C. H. Nightingale. 1995. Antibiotic kinetics and dynamics for the clinician. Antimicrob. Ther. Med. Clin. N. Am. 79: 477-495.
27. Sarasola, P., P. Lees, F. AliAbadi, Q. A. McKellar, W. Donachie, K. A. Marr, S. J. Sunderland, and T. G. Rowan. 2002. Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. Antimicrob. Agents Chemother. 46:3013-3019.
28. Shojaee AliAbadi, F. 1997. Danofloxacin pharmacodynamic and pharmacokinetic inter-relationships in ruminant species. Ph.D. thesis. University of London, London, United Kingdom.
29. Shojaee AliAbadi, F., and P. Lees. 1997. Pharmacodynamic and pharmacokinetic inter-relationships of antibacterial drugs. J. Vet. Pharmacol. Ther. 20:14-17.
30. Shojaee AliAbadi, F., and P. Lees. 2000. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation. Int. J. Anqtimicrob. Agents 14:307-313.
31. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antibacterial pharmacokinetic parameters with therapeutic efficacy in animal models. J. Infect. Dis. 158:831-847.
32. Wolfson, J. S., and D. C. Hooper. 1989. Fluroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2:378-424.
33. Wolfson, J. S., and D. C. Hooper. 1991. Pharmacokinetics of quinolones: newer aspects. Eur. J. Clin. Microbiol. Infect. Dis. 10:267-274.